Form 4: Oramed CEO Donates 100,000 Shares in Charitable Gift

Oramed Pharmaceuticals Inc. President and CEO Nadav Kidron reported a charitable donation of 100,000 common shares.

Summary

• Nadav Kidron, President and CEO, Director, and 10% Owner of ORAMED PHARMACEUTICALS INC. (ORMP), reported a change in beneficial ownership.
• The transaction involved the disposition of 100,000 shares of Common Stock on March 12, 2026.
• This disposition was a charitable donation (Transaction Code G), for which no price was reported as no value was received.
• Following the transaction, Nadav Kidron directly beneficially owns 3,255,238 shares of Common Stock.
• The reporting person is not affiliated with, and has no control over, the donee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While a charitable donation by a CEO can be seen positively for corporate image, it also represents a reduction in direct insider ownership, which is a minor negative from an investment perspective, balancing the overall sentiment.

Positives

• Demonstrates philanthropic activity by a key executive, potentially enhancing the company's public image and corporate social responsibility profile.

Negatives

• A reduction of 100,000 shares in direct beneficial ownership by the President and CEO, though for charitable purposes, slightly decreases insider stake.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transaction represents a charitable donation and is not a market transaction, thus no price has been reported.
• No value was received for the donated shares.
• The Reporting Person is not affiliated with, and has no control over, the donee.

Industry Context

StockSavvy.ai notes that insider transactions, even charitable ones, are routinely disclosed via Form 4 filings to ensure transparency in executive stock holdings. While not indicative of operational performance, such disclosures provide insight into management's personal stake in the company.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the charitable nature of the transaction mitigates any negative interpretation typically associated with insider selling.
• Public/Community: Potentially positive public relations for the company due to the CEO's philanthropic activity.

Key Dates

Keywords

Oramed Pharmaceuticals, ORMP, Nadav Kidron, Insider Transaction, Form 4, Share Donation, Beneficial Ownership, CEO Stock, Philanthropy